MESO Mesoblast Ltd
- Stocks
- Healthcare
- NASDAQ: MESO
Price (delayed)
$15.15
Market cap
$1.94B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.85
Enterprise value
$1.91B
Relative Growth:
Rel. Growth:
29
Relative Strength:
Rel. Strength:
72
Relative Valuation:
Rel. Valuation:
5
Relative Profitability:
Rel. Profitability:
23
mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells
Highlights
The company's revenue has surged by 191% YoY
The company's gross profit has surged by 104% YoY
The gross margin fell by 30% YoY
Mesoblast's net income has decreased by 16% YoY
Key stats
What are the main financial stats of MESO
Market
Valuations
Earnings
Shares outstanding
128M
Market cap
$1.94B
Enterprise value
$1.91B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.92
Price to sales (P/S)
101.52
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
110.81
Revenue
$17.2M
Gross profit
$12.07M
Operating income
-$59M
Net income
-$102.14M
EBIT
-$78.84M
EBITDA
-$78.84M
Free cash flow
-$50.63M
Per share
Balance sheet
Liquidity
EPS
-$0.85
EPS diluted
-$0.85
Free cash flow per share
-$0.44
Book value per share
$5.18
Revenue per share
$0.15
TBVPS
$1.85
Total assets
$784.68M
Total liabilities
$187.24M
Debt
$128.16M
Equity
$597.44M
Working capital
$101.72M
Debt to equity
0.21
Current ratio
1.99
Quick ratio
1.72
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
-458.4%
Gross margin
70.2%
Net margin
-593.9%
Operating margin
-343%
Return on assets
-14.1%
Return on equity
-19%
Return on invested capital
-103.1%
Return on capital employed
-11.6%
Return on sales
-458.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MESO stock price
How has the Mesoblast stock price performed over time
Intraday
-2.51%
1 week
-7.79%
1 month
-12.53%
1 year
73.54%
YTD
-23.48%
QTD
-5.96%
Financial performance
How have Mesoblast's revenue and profit performed over time
Revenue
$17.2M
Gross profit
$12.07M
Operating income
-$59M
Net income
-$102.14M
Gross margin
70.2%
Net margin
-593.9%
The company's revenue has surged by 191% YoY
The company's gross profit has surged by 104% YoY
The operating margin has surged by 64% year-on-year
The net margin has surged by 60% year-on-year
Price vs fundamentals
How does MESO's price correlate with its fundamentals
Growth
What is Mesoblast's growth rate over time
Valuation
What is Mesoblast stock price valuation
P/E
N/A
P/B
2.92
P/S
101.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
110.81
The EPS has increased by 4.5% YoY
The stock's P/B is 36% above its last 4 quarters average of 2.2
Mesoblast's equity has increased by 24% YoY
The company's revenue has surged by 191% YoY
The stock's price to sales (P/S) is 32% less than its last 4 quarters average of 153.2
Efficiency
How efficient is Mesoblast business performance
The ROS has soared by 58% YoY
MESO's ROIC is down by 36% YoY
The ROA has contracted by 8% YoY
MESO's ROE is down by 6% year-on-year
Dividends
What is MESO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MESO.
Financial health
How did Mesoblast financials performed over time
MESO's current ratio has surged by 69% year-on-year
The quick ratio rose by 50% YoY
The debt is 79% smaller than the equity
Mesoblast's equity has increased by 24% YoY
Mesoblast's debt to equity has decreased by 16% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.